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Abstract 
Introduction 
Invasive aspergillosis (IA) is a fungal infection that particularly affects immunocompromised 
hosts. Recently, several reports have indicated a high incidence of IA in intensive care unit 
(ICU) patients. However, few data are available on the epidemiology and outcome of patients 
with IA in this setting. 
Methods 
An observational study including all patients with a positive Aspergillus culture during ICU 
stay was performed in 30 ICUs in eight countries. Cases were classified as proven IA, 
putative IA or Aspergillus colonization according to recently validated criteria. 
Demographics, microbiological and diagnostic data were collected. Outcome was recorded 
12 weeks after Aspergillus isolation. 
Results 
A total of 563 patients were included of whom 266 were colonized (47%), 203 had putative 
IA (36%) and 94 proven IA (17%). The lung was the most frequent site of infection (94%) 
and Aspergillus fumigatus the most commonly isolated species (92%). Patients with IA had 
more incidences of cancer and organ transplantation than those with colonization; they were 
also more frequently diagnosed with sepsis on ICU admission and more frequently received 
vasopressors and renal replacement therapy (RRT) during the ICU stay than other patients. 
Mortality was 38% among colonized patients, 67% in those with putative IA and 79% in 
proven IA (P <0.001). Independent risk factors for death among patients with IA included 
older age, history of bone marrow transplantation, and mechanical ventilation, RRT and 
higher Sequential Organ Failure Assessment (SOFA) scores at diagnosis. 
Conclusions 
IA among critically ill patients is associated with high mortality. Patients diagnosed with 
proven or putative IA had greater severity of illness and more frequently needed organ 
support than those with Aspergillus spp colonization. 
Introduction 
Invasive aspergillosis (IA) is a serious opportunistic infection that mainly affects 
immunocompromised patients, such as those with prolonged neutropenia and cancer [1]. As 
such, most research on the epidemiology and clinical impact of Aspergillus spp. infection has 
been conducted in patients with hematological malignancies or after stem cell and solid organ 
transplantation [2,3]. However, several reports have shown that Aspergillus spp. can cause 
invasive disease in other categories of patients, including those admitted to intensive care 
units (ICUs) [4-8]. In this setting, clinical diagnosis of IA is a real challenge, as standard 
diagnostic definitions were developed and have been validated only for patients with cancer 
or after hematopoietic stem cell transplants and cannot necessarily be extrapolated to 
critically ill patients, who lack specific host factors as defined by the European Organization 
for Research and Treatment of Cancer (EORTC) [9]. 
Although IA has been considered a rare condition among critically ill patients [10-12], recent 
data indicate that it should be reconsidered as an emerging and devastating infectious disease 
in this population. Indeed, in an 18-month surveillance program involving 18 Italian ICUs, 
only 12 cases of IA occurred in 5561 patients (0.2%); mortality among these patients was 
60% [13]. Also, another study reported 7% of patients with IA, adding up to a mortality rate 
of 91%; interestingly, 70% of these patients had no predisposing factors for invasive fungal 
disease [14]. Moreover, in ICU patients, IA may potentially affect multiple organs, evolving 
into a disseminated disease, which remains largely under-diagnosed and is associated with 
poor outcome [15]. 
In clinical practice, a diagnosis of IA is frequently suspected when Aspergillus is isolated 
from non-sterile body sites, particularly tracheal and bronchial aspirates [16]. However, since 
Aspergillus spp. are ubiquitous, one must be cautious in ascribing a pathogenic role to the 
fungus obtained from these samples. Moreover, the impact of Aspergillus spp. isolates from 
respiratory cultures on the occurrence of IA has been extensively studied in 
immunocompromised patients but little is known about this effect in other populations, 
including ICU patients [17,18]. The presence of other risk factors, such as chronic lung and 
liver disease or general debilitation, may strengthen the likely clinical relevance of a positive 
Aspergillus culture [15]; nevertheless, invasive diagnostic procedures, such as lung biopsy, 
which are necessary to confirm a diagnosis of Aspergillus infection, are often not feasible in 
patients with severe respiratory insufficiency and critical illness [19-21]. Moreover, non-
invasive diagnostic tests, such as galactomannan (GM) determination, have been integrated 
into a diagnostic algorithm that has been validated only for patients with bone marrow 
transplant and cancer, and needs to be further studied in ICU patients [5,22]. 
The aim of this study was, therefore, to collect data from a large series of ICU patients with 
either Aspergillus colonization or invasive disease, in order to investigate the epidemiology 
of IA in this population. 
Material and methods 
Patients and setting 
This was an international, multicenter (n = 30) observational study of ICU patients with 
evidence of either Aspergillus colonization or IA (AspICU Study). All consecutive adult (>18 
years) ICU patients with a culture and/or direct examination and/or histopathological sample 
positive for Aspergillus spp. at any site between January 2000 and January 2011 were eligible 
for inclusion. Patients with a post-mortem diagnosis of IA were also eligible. Data were 
collected prospectively. However, because we anticipated a relative paucity of patients in 
which histopathology data were available we accepted patients from historical cohorts (as 
from January 2000) on the condition that none of the requested data was missing. Clinical 
suspicion of IA prior to ICU admission was an exclusion criterion. The study was approved 
by the local ethics committee/institutional review board of each participating center 
(Appendix 1) and, because of the observational nature of the study and the lack of any 
modification in the general management of these patients, the need for informed consent was 
waived. A complete and detailed description of the study methodology has been reported 
elsewhere [23]. 
Data collection and outcomes 
Data were collected from patient medical records and submitted via a web-based registration 
system [24]. Collected patient data included: demographics (age, weight, height, sex); 
underlying diseases; and acute illness severity scores, including Acute Physiology And 
Chronic Health Evaluation (APACHE) II score on admission [25] and Sequential Organ 
Failure Assessment (SOFA) score [26] on the day of the positive Aspergillus culture. Acute 
respiratory distress syndrome (ARDS) was defined according to the 1994 Consensus 
Conference criteria [27]. Sepsis was defined according to standard criteria [28]. We also 
collected clinical data, including signs compatible with invasive fungal disease (i.e. refractory 
or recrudescent fever, pleuritic chest pain or rub, dyspnea, hemoptysis or worsening lung 
function). Sampling techniques and sites, as well as mycological tests (including GM 
measurements and Aspergillus PCR, whenever available) to support a diagnosis of IA, were 
recorded. Test results were interpreted as positive if they met international consensus criteria 
[5,9,29]; in particular, GM was considered abnormal with an optical density index >0.5. 
Organs affected by Aspergillus and species identification were recorded. Radiologic data 
included findings from chest X-rays or computed tomography (CT) scans from involved 
organs (chest, sinuses, abdomen and central nervous system). Findings on chest CT-scan 
suggestive of invasive fungal disease were defined as “typical” with at least one of the 
following: wedge-shaped lesion, halo or air-crescent sign, lung cavitation or nodule [9]. 
The time of diagnosis of IA was considered as the date of the first positive Aspergillus culture 
or as the date of clinical deterioration compatible with fungal disease in case of post-mortem 
diagnosis. Although the “clinical” diagnosis of IA was reported in the database according to 
the judgment of the attending physicians, the final diagnosis was obtained using a central 
adjudication committee for the various diagnostic categories according to (a) the 
EORTC/Mycosis Study Group (MSG) (proven, probable, possible invasive aspergillosis or 
not-classifiable) criteria [9] and (b) “validated” criteria to discriminate Aspergillus 
colonization from IA in critically ill patients (putative or proven IA; Appendix 2) [23]. 
Among those patients with putative or proven IA, we separately analyzed those who had 
EORTC host-factors for immunosuppression (i.e. recent history of neutropenia (<500 
neutrophils/mm
3
); receipt of an allogeneic stem cell transplant; prolonged use of 
corticosteroids at a mean minimum dose of 0.3 mg/kg/day of prednisone equivalent for 13 
weeks; treatment with other recognized T-cell immunosuppressants; inherited severe 
immunodeficiency) [9] from others. Data were also collected on antifungal therapy and its 
duration as well as outcomes, including length of ICU stay, 12-week survival rates and use of 
mechanical ventilation and/or renal replacement therapy (RRT) or vasopressor agents, both at 
the time of the first Aspergillus-positive culture and during the ICU stay. 
Statistical analysis 
Statistical analyses were performed using the SPSS 18.0 for Windows NT software package 
(SPSS Inc. 2004, Chicago, IL, USA). Descriptive statistics were computed for all study 
variables; discrete variables are expressed as counts (percentage) and continuous variables as 
mean ± standard deviation or median [1
st–3rd quartile]. Differences between the three study 
groups were assessed using chi-square test, Fisher’s exact test, Student’s t-test, or Mann–
Whitney U test, as appropriate. A time-to-death analysis was performed until 84 days (12 
weeks) after the first positive culture for Aspergillus. The Kaplan-Meier method with log-
rank test was used to compare the survival curves of the three populations (colonization, 
putative IA and proven IA) over time. This long-rank test was then adjusted for all clinically 
relevant variables that could affect outcome (i.e., age; sex; medical admission; sepsis on 
admission; acute respiratory distress syndrome [ARDS] on admission; diagnostic category, 
APACHE II score on admission; bone marrow transplantation; comorbidities; SOFA score on 
the day of positive Aspergillus culture; lung involvement; comorbidities; EORTC criteria for 
IA; antifungal therapy; vasopressors; mechanical ventilation; RRT). The hazard ratio for 
death (HR) and 95% confidence intervals (CI) were also reported. Multivariable logistic 
regression analysis with mortality as the dependent variable was performed in patients with 
putative/proven IA; only variables associated with a higher risk of 12-week mortality (p < 
0.2) on a univariate basis were introduced in the multivariate model. Co-linearity between 
variables was excluded prior to modeling. Odds ratios (OR) with 95% CI were computed. All 
tests were two-sided and a p < 0.05 was considered as statistically significant. 
Results 
Characteristics of the study cohort 
A total of 563 patients were included in the study from 30 ICUs in eight countries (Belgium, 
France, Brazil, China, Spain, Greece, India and Portugal). Characteristics of the cohort are 
shown in Table 1. Most patients were medical admissions (n = 392, 70%). The most common 
reasons for ICU admission were respiratory (n = 222, 39%) and cardiovascular (n = 147, 
26%) disease. The most common comorbid conditions were chronic obstructive pulmonary 
disease (COPD, n = 174, 31%) and diabetes (n = 92, 16%); 59 (11%) patients were receiving 
immunosuppressive therapy and 256 (45%) corticosteroids, with 168 (30%) on prolonged 
(>30 days) corticosteroid therapy. Sepsis and ARDS were diagnosed on admission in 222 
(39%) and 57 (10%) patients, respectively. Fifty-six patients (10%) had undergone solid 
organ transplantation. Neutropenia was present in 40 patients (6%), but prolonged 
neutropenia (>10 days) in only 3 patients. 
Table 1 Characteristics of the study cohort on ICU admission 
 All patients (n = 
563) 
Proven IA (n = 
94) 
Putative IA (n = 
203) 
Colonization (n = 
266) 
Age (years) 61 ± 17 60 ± 13 62 ± 16 61 ± 18 
Male, n (%) 341 (61) 54 (57) 127 (63) 160 (60) 
BMI (kg/m
2
) 24 [21–27] 24 [21–26] 23 [20–27] 25 [22–28] 
Underlying conditions     
No underlying disease, n (%) 76 (14) 4 (4) * 11 (5) * 61 (23) 
COPD, n (%) 174 (31) 22 (23) 
#
 80 (39) * 72 (27) 
Chronic heart failure, n (%) 55 (10) 8 (9) 19 (9) 28 (11) 
Diabetes, n (%) 92 (16) 19 (19) 33 (16) 40 (15) 
Solid tumor, n (%) 58 (10) 13 (14) 21 (9) 24 (9) 
Hematologic cancer/BMT, n (%) 48 (8) 15 (16) * 31 (15) * 6 (2) 
Neutropenia, n (%) 40 (7) 5 (5) * 18 (9) * 3 (1) 
Radiotherapy/chemotherapy, n (%) 53 (9) 12 (13) * 33 (16) * 8 (3) 
Solid organ transplantation, n (%) 56 (10) 19 (20) * 28 (14) * 9 (4) 
Immunosuppressive drugs, n (%) 59 (11) 27 (29) * 
#
 25 (12) * 7 (3) 
HIV, n (%) 5 (1) 1 (1) 1 (1) 3 (1) 
Liver disease, n (%) 40 (7) 13 (14) * 14 (7) 13 (5) 
Chronic hemodialysis, n (%) 22 (4) 3 (3) 8 (4) 11 (4) 
Smoking, n (%) 88 (16) 15 (16) 28 (14) 45 (17) 
Alcohol abuse, n (%) 54 (10) 9 (10) 16 (8) 29 (11) 
Diagnostic category     
Medical admission, n (%) 392 (70) 79 (84) * 
#
 94 (46) * 152 (57) 
Cardiovascular 147 (26) 29 (30) 49 (24) 69 (26) 
Respiratory 222 (39) 38 (41) * 
#
 107 (53) * 77 (29) 
Neurological 32 (6) 3 (3) * 3 (2) * 26 (10) 
Intoxication 5 (1) 0 1 (1) 4 (2) 
Gastro-intestinal 37 (7) 6 (7) 13 (6) 18 (7) 
Endocrine 18 (3) 8 (9) * 10 (5) * 0 
Post-operative 48 (9) 7 (8) 15 (7) 26 (10) 
Trauma 47 (8) 2 (2) * 3 (2) * 42 (16) 
Others 7 (1) 1 (1) 2 (1) 4 (1) 
Severity scores & Main diagnoses     
APACHE II score on admission 23 [17–28] 24 [18–28] 25 [17–30] 23 [17–28] 
Sepsis on ICU admission 222 (39) 47 (51) * 94 (46) * 81 (30) 
ARDS on ICU admission 57 (10) 24 (26) * 
#
 21 (10) * 12 (4) 
Septic shock, n (%) 64 (11) 14 (15) * 29 (14) * 21 (8) 
Traumatic brain injury, n (%) 28 (5) 0 * 1 (1) * 27 (10) 
Pneumonia, n (%) 72 (13) 15 (16) 29 (14) 28 (11) 
Other brain injuries, n (%) 23 (4) 1 (1) * 2 (1) * 20 (8) 
Acute heart failure/CABG, n (%) 39 (7) 3 (3) * 6 (3) * 30 (11) 
Pancreatitis, n (%) 7 (1) 1 (1) 1 (1) 5 (1) 
Prophylactic antifungals, n (%) 32 (6) 8 (9) * 19 (9) * 5 (2) 
Antifungal therapy, n (%) 285 (51) 78 (85) * 
#
 147 (72) * 60 (22) 
Duration of therapy, days 
$
 13 [6–28] 10 [4–24] 12 [7–29] 18 [9–28] 
* p < 0.05 vs. Colonization; 
#
 p < 0.05 vs. Putative. 
$
 calculated among those patients on therapy. 
BMI = body mass index; COPD = chronic obstructive pulmonary disease; BMT = bone marrow transplantation; 
HIV = human immunodeficiency virus; APACHE = Acute Physiology and Chronic Health Evaluation; ICU = 
intensive care unit; ARDS = acute respiratory distress syndrome; RRT = renal replacement therapy; CABG = 
coronary artery bypass graft. 
From the cohort of 563 patients, 94 had proven IA (17%), 203 had putative IA (36%), and 
266 were colonized (47%) when “validated” criteria were used. It would not have been 
possible to classify 438 (77%) of the patients if only the EORTC/MSG criteria had been used. 
Aspergillus fumigatus was the most commonly isolated species (n = 519, 92%). 
Clinical signs and medical imaging 
Clinical and radiological findings are reported in Table 2. Chest computed tomography (CT) 
was performed in 223 (40%) patients, broncho-alveolar lavage (BAL) in 225 (40%) patients 
and serum or BAL GM measured in 151 (27%) patients. There were significantly more 
radiological findings typical of IA on chest CT-scan in patients with proven or putative IA 
than in those with colonization. CT-scan of the sinuses was performed in 24 patients and 15 
of the scans were abnormal. Five of the 24 patients had sinus cultures positive for 
Aspergillus; all 5 had abnormal CT-scan findings, but 3 were diagnosed as colonization and 2 
as putative IA. Abdominal CT-scan was performed in 38 patients and 24 of the scans were 
abnormal. Three of the 38 patients had positive Aspergillus cultures on abdominal samples (2 
in hepatic and one in peritoneal samples); all had abnormal CT-scan findings and were 
diagnosed as proven IA. Cerebral CT-scan was performed in 45 patients and 30 of the scans 
were abnormal. Nine of the 45 patients had positive Aspergillus cultures on cerebral samples, 
either cerebrospinal fluid (CSF) or brain biopsy; all had abnormal CT-scan findings and were 
diagnosed as proven IA. One additional patient, in whom no cerebral CT was performed, had 
CSF cultures positive for Aspergillus. 
Table 2 Clinical, radiological and microbiological findings related to Aspergillus 
diagnosis 
 All patients  
(n = 563) 
Proven IA  
(n = 94) 
Putative IA  
(n = 203) 
Colonization  
(n = 266) 
ICU stay before first positive culture 4 [1–9] 4 [1–11] 4 [2–10] 4 [2–9] 
SOFA II score on diagnosis 8 [4–12] 11 [7–14] * # 9 [6–12] * 5 [3–10] 
Clinical signs     
At least of the following signs, n (%) 317 (56) 73 (77) * 141 (69) * 103 (39) 
Refractory fever, n (%) 163 (29) 53 (57) * 
#
 68 (34) * 42 (16) 
Recrudescent fever, n (%) 18 (3) 4 (3) 7 (3) 7 (3) 
Pleuritic chest pain, n (%) 18 (3) 5 (5) 8 (4) 5 (2) 
Pleuritic rub, n (%) 6 (1) 3 (3) 0 3 (1) 
Dyspnea, n (%) 257 (46) 45 (48) * 
#
 129 (64) 83 (31) 
Hemoptysis, n (%) 32 (6) 14 (15) * 
#
 13 (6) 5 (2) 
Worsening lung function, n (%) 219 (39) 61 (66) * 118 (58) * 40 (15) 
Abnormal Radiologic Findings 487 (87) 94 (100) * 203 (100) * 191 (71) 
Chest X-rays / CT-scan, n (%) 515 (91) / 223 
(40) 
86 (92) / 62 (67) 
* 
#
 
192 (95) / 96 
(47) * 
237 (89) / 65 
(24) 
Non-specific chest CT-scan findings 135/223 33/62 * 55/96 * 57/65 
“Typical” chest CT-scan findings 84/223 29/62 * 41/96 * 4/65 
Microbiological findings     
BAL/ETA, n (%) 477 (96) 79 (92) 182 (98) 216 (97) 
BAL performed, n (%) 225 (40) 56 (60) * 112 (55) * 57 (21) 
Positive GM, n/mes (%) 86/151 (57) 44/52 (84) * 31/37 (84) * 11/62 (18) 
β-D-Glucan, n/mes (%) 3/6 (50) 0 3/5 (60) 0/1 (0) 
PCR, n/mes (%) 4/4 (100) 0 3/3 (100) 1/1 (100) 
Performed biopsy/autopsy, n (%) 72/61 (24) 93 (100) * 
#
 15 (7) 25 (9) 
Isolated species     
Aspergillus fumigatus, n (%) 519 (92) 83 (88) 182 (90) 254 (96) 
Aspergillus flavus, n (%) 19 (3) 2 (2) 12 (6) 5 (2) 
Aspergillus niger, n (%) 7 (1) 2 (2) 2 (1) 3 (1) 
Others, n (%) 18 (3) 7 (8) 7 (3) 4 (2) 
EORTC Host Factors     
EORTC host factor present on diagnosis, n (%) 249 (44) 65 (70) * 143 (70) * 41 (15) 
Neutropenia, n (%) 34 (6) 8 (9) * 21 (10) * 5 (2) 
Malignancy under cytotoxic therapy, n (%) 66 (12) 18 (19) * 37 (18) * 11 (4) 
Glucocorticoid treatment, n (%) 256 (45) 59 (63) * 
#
 156 (78) * 42 (15) 
Inherited Severe Immunodeficiency, n (%) 11 (2) 3 (3) 6 (3) 0 
Organ support at time of diagnosis     
Vasopressor therapy, n (%) 346 (61) 63 (67) * 138 (68) * 145 (55) 
RRT, n (%) 155 (28) 48 (51) * 
#
 61 (30) * 46 (18) 
Mechanical ventilation, n (%) 482 (86) 92 (98) * 
#
 177 (87) 214 (80) 
Organ support during ICU stay     
Vasopressor therapy, n (%) 429 (76) 78 (83) * 168 (83) * 183 (69) 
RRT, n (%) 182 (32) 57 (60) * 
#
 71 (35) * 54 (21) 
Mechanical ventilation, n (%) 506 (90) 86 (91) 187 (92) 233 (87) 
* p < 0.05 vs. Colonization; 
#
 p < 0.05 vs. Putative. 
ICU = intensive care unit; SOFA = Sepsis Organ Failure Assessment; CT = computed tomography; BAL = 
broncho-alveolar lavage; ETA = endotracheal aspirate; GM = galactomannan; PCR = polymerase chain 
reaction; EORTC = European Organization for Research and Treatment of Cancer; RRT = renal replacement 
therapy. 
Affected site and diagnostic classification 
The most commonly affected site was the lung/trachea (92%) (Figure 1). Only 16% of the 
patients with positive Aspergillus culture in the lung/trachea had proven IA, whereas almost 
all patients with positive cultures in the abdominal, brain and endovascular samples were 
diagnosed as proven IA. Two positive abdominal samples were considered as colonization as 
they originated from indwelling drains; the other 9 patients had liver (n = 5) or peritoneal (n = 
4) involvement. Twenty-eight patients had more than one site affected (22 had two and 6 had 
three affected sites). Six patients with positive lung cultures were classified as “proven” 
because of non-pulmonary proven IA; 9/10 patients with brain involvement and 8/8 with 
endovascular IA had also pulmonary positive cultures. Three of the patients with positive 
abdominal cultures (i.e. proven disease) had also proven pulmonary IA. The seven patients 
with putative infection in the skin (n = 4) or the sinus (n = 3) were classified as such because 
of concomitant putative pulmonary localization; in particular, specific skin biopsy was not 
performed in any patient to confirm cutaneous aspergillosis, except in one (proven disease). 
Figure 1 Number of sites affected by Aspergillus spp for the different diagnostic 
categories: PR = proven; PT = putative; CO = colonization – data are reported as 
number (%). In case of multiple sites being positive for Aspergillus spp, the patient has been 
counted more than once. 
Patients with putative or proven IA were more likely to have hematological cancer and to 
have undergone bone marrow or solid organ transplantation than those with Aspergillus 
colonization, which likely explains the larger proportion of patients receiving chemotherapy, 
radiotherapy and immunosuppressive drugs in these groups. Patients with putative or proven 
IA were also more frequently admitted for a medical reason and were more likely to have a 
diagnosis of sepsis or ARDS on ICU admission. Although radiological findings were 
abnormal in all patients with proven or putative IA, no more than 40% had chest CT-scan 
findings that were considered “typical” of IA. Where available, serum or BAL GM 
measurements were abnormal in more than 80% of patients with proven or putative IA, 
compared to only 18% of patients with colonization. Patients with proven and putative IA 
had a higher SOFA score on the day of the first positive Aspergillus culture than colonized 
patients; these patients also had a greater requirement for mechanical ventilation, 
vasopressors or RRT during the ICU stay. 
In patients with proven IA, COPD was less frequently observed than in putative IA patients; 
in addition, compared to patients with putative IA, patients with a proven diagnosis were 
more frequently treated with immunosuppressive drugs, more frequently admitted for 
medical reasons, had a greater incidence of respiratory diseases and ARDS on ICU 
admission, and higher SOFA scores on IA diagnosis. On the day of diagnosis, patients with 
proven IA had more compatible clinical signs (fever refractory to antibacterial therapy, 
dyspnea and hemoptysis) than those with putative IA, as well as more non-specific findings 
on CT-scan. Most of the extra-thoracic cases of Aspergillus were in patients with proven IA, 
on the basis of analysis of fluids from sterile body sites or biopsies. Finally, RRT therapy was 
more commonly used among patients with proven IA. Antifungal therapy was initiated in 285 
(51%) patients; in 31 additional cases, therapy was not administered because either clinical 
decision or post-mortem diagnosis. The median time from positive Aspergillus culture to 
initiation of therapy was 2 [0–5] days for patients with Aspergillus colonization and 1 [0–3] 
days for both proven and putative IA. 
Immunocompromised Patients 
Among those patients with putative or proven IA, 208 (70%) had an immunosuppressive 
state, according to EORTC criteria (Table 3). Immunocompromised patients had similar 
severity of disease than others and presented more respiratory failure and fewer traumas as 
reasons for ICU admission. They also received more prophylactic antifungal therapy than 
others and were less likely to be on RRT on IA diagnosis. 
Table 3 Main differences among patients with putative or proven IA, with regard to the 
presence of immunosuppression 
 Immunosuppression  
(n = 208) 
No-Immunosuppression  
(n = 89) 
p value 
Age (years) 61 ± 15 63 ± 15 0.15 
Male, n (%) 127 (61) 53 (60) 0.92 
BMI (kg/m
2
) 23 [20–27] 24 [21–28] 0.77 
Underlying conditions    
COPD, n (%) 67 (32) 35 (39) 0.23 
Chronic heart failure, n (%) 14 (7) 13 (15) 0.06 
Diabetes, n (%) 28 (14) 24 (27) 0.02 
Liver disease, n (%) 16 (8) 11 (12) 0.19 
Chronic hemodialysis, n (%) 6 (3) 5 (6) 0.25 
Smoking, n (%) 24 (12) 19 (21) 0.03 
Alcohol abuse, n (%) 12 (6) 15 (17) 0.002 
Diagnostic category    
Medical admission, n (%) 170 (82) 69 (78) 0.08 
Cardiovascular, n (%) 49 (24) 29 (33) 0.1 
Respiratory, n (%) 112 (54) 33 (37) 0.008 
Neurological, n (%) 4 (2) 2 (2) 0.85 
Intoxication, n (%) 1 (1) 0 0.51 
Gastro-intestinal, n (%) 11 (5) 8 (9) 0.23 
Endocrine, n (%) 13 (6) 5 (6) 0.83 
Post-operative, n (%) 18 (9) 4 (4) 0.21 
Trauma, n (%) 0 5 (6) 0.006 
Others, n (%) 2 (1) 1 (1) 0.89 
Severity scores & Main diagnoses    
APACHE II score on admission 25 [17–30] 23 [17–28] 0.29 
Sepsis on ICU admission 103 (50) 38 (42) 0.07 
ARDS on ICU admission 33 (16) 22 (25) 0.07 
Septic shock, n (%) 28 (13) 16 (18) 0.31 
Traumatic brain injury, n (%) 1 (1) 0 0.51 
Pneumonia, n (%) 27 (13) 17 (19) 0.17 
Other brain injuries, n (%) 3 (1) 0 0.25 
Acute heart failure/CABG, n (%) 1 (1) 8 (9) <0.001 
Pancreatitis, n (%) 2 (1) 0 0.35 
Prophylactic antifungals, n (%) 24 (12) 3 (3) 0.03 
Antifungal therapy, n (%) 159 (76) 66 (74) 0.67 
Time from diagnosis to therapy, days 1 [0–3] 1 [0–4] 0.34 
Duration of therapy, days 
$
 11 [6–25] 14 [5–28] 0.83 
ICU stay before first positive culture 4 [2–11] 4 [2–10] 0.76 
SOFA II score on diagnosis 10 [6–13] 9 [6–12] 0.15 
Organ support at time of diagnosis    
Vasopressor therapy, n (%) 139 (67) 62 (70) 0.63 
RRT, n (%) 67 (32) 42 (47) 0.01 
Mechanical ventilation, n (%) 188 (90) 81 (91) 0.87 
Organ support during ICU stay    
Vasopressor therapy, n (%) 173 (83) 73 (82) 0.81 
RRT, n (%) 83 (40) 45 (51) 0.09 
Mechanical ventilation, n (%) 190 (91) 83 (93) 0.58 
12-week Mortality, n (%) 151 (73) 59 (66) 0.27 
BMI = body mass index; COPD = chronic obstructive pulmonary disease; APACHE = Acute Physiology and 
Chronic Health Evaluation; ICU = intensive care unit; ARDS = acute respiratory distress syndrome; RRT = 
renal replacement therapy; CABG = coronary artery bypass graft. 
Outcomes 
The length of ICU stay was similar in patients with proven IA, putative IA and colonization 
(15 [8-23,25-33] days vs. 17 [9-23,25-36] days vs. 14 [6-23,25-31] days, p = 0.07). Mortality 
at 12-weeks was significantly higher in patients with proven IA (74/94, 79%) than in those 
with putative IA (136/203, 67%, p = 0.03) or colonization (101/ 266, 38%, p < 0.001). 
Patients with pulmonary involvement had mortality rates of 55% (71% if proven IA, 68% if 
putative IA and 39% if Aspergillus colonization), which were similar to the rates in patients 
with skin/wound and sinus involvement (55% and 37%, respectively). The highest mortality 
rates were observed in patients with abdominal (81%), cerebral (90%) or endovascular (86%) 
involvement. Among patients with putative or proven IA, mortality was similar between 
those with EORTC criteria for immunosuppression and others (73% vs. 66%, p = 0.27). The 
use of antifungal therapy was not associated with differences in overall survival when 
compared to untreated patients. Also, the delay between the first positive Aspergillus culture 
and the initiation of antifungal therapy was not associated with outcome. 
At 84 days, patients with putative and proven IA had significantly lower survival rates than 
those with colonization (Figure 2, log-rank p < 0.001). After adjustment for several 
confounders, this difference remained significant only for proven IA (Table 4). Among 
patients with proven or putative IA, independent risk factors for mortality were older age, 
bone marrow transplantation, a higher SOFA score and need for mechanical ventilation or 
RRT on the day of positive Aspergillus culture (Table 5). 
Figure 2 Survival curves for different diagnostic categories, using the criteria of the 
clinical algorithm. Log-rank for survival distributions was p < 0.001 when putative or 
proven IA were compared to colonization. Log-rank for survival distribution between 
putative and proven IA was p = 0.156. 
Table 4 Mortality risk of putative and proven invasive aspergillosis relative to 
Aspergillus colonization 
 Unadjusted Adjusted 
  95% CI for HR   95% CI for HR  
 HR Lower Upper p value HR Lower Upper p value 
Colonization 1.00    1.00    
Putative IA 2.18 1.68 2.83 < 0.001 1.18 0.93 1.81 0.16 
Proven IA 3.12 2.30 4.24 < 0.001 1.51 1.00 2.26 0.05 
HR = hazard ratio; CI = confidence interval. 
Table 5 Risk factors for mortality among patients with proven or putative invasive 
aspergillosis (IA) 
Variable Univariable analysis Multivariable analysis 
 P value OR (95% CI) P value OR (95% CI) 
Age, years 0.008 1.023 [1.006-1.040] 0.001 1.034 [1.014-1.055] 
Male 0.264 0.751 [0.455-1.241]   
BMI 0.024 1.069 [1.009-1.133]   
Septic shock 0.689 1.158 [0.565-2.374]   
Pneumonia 0.880 0.948 [0.476-1.888]   
Primary brain injury 0.216 0.218 [0.020-2.437]   
Acute cardiac failure 0.225 3.655 [0.450-29.660]   
Sepsis on admission 0.110 1.503 [0.912-2.478]   
APACHE on admission 0.003 1.049 [1.017-1.083]   
Diabetes 0.576 1.211 [0.619-2.371]   
Chronic heart disease 0.030 3.890 [1.140-13.266]   
COPD 0.605 0.872 [0.520-1.463]   
Liver failure 0.070 2.749 [0.922-8.192]   
HIV 0.564 0.441 [0.027-7.132]   
Smoking 0.937 1.029 [0.509-2.078]   
Alcohol 0.298 0.639 [0.276-1.483]   
Chronic dialysis 0.148 4.615 [0.582-36.603]   
Bone marrow transplantation 0.013 3.875 [1.326-11.327] 0.039 3.352 [1.060-10.598] 
Solid tumor 0.085 2.241 [0.894-5.617]   
Cancer 0.769 1.101 [0.579-2.094]   
Neutropenia 0.646 0.827 [0.368-1.858]   
Chemotherapy/radiotherapy 0.525 0.802 [0.405-1.586]   
Solid organ transplantation 0.877 1.055 [0.534-2.084]   
Corticosteroids 0.248 1.376 [0.801-2.366]   
Immune deficit 0.117 0.342 [0.090-1.306]   
Aspergillus species 0.040 2.183 [1.038-4.592]   
Lung involvement 0.998 1.001 [0.300-3.340]   
SOFA score at diagnosis <0.001 1.180 [1.107-1.256] <0.001 1.140 [1.062-1.224] 
Vasopressor therapy at diagnosis <0.001 4.309 [2.299-8.078]   
Mechanical ventilation at diagnosis <0.001 6.498 [2.590-16.303] 0.009 3.916 [1.408-10.891] 
Renal replacement therapy at diagnosis <0.001 3.293 [1.895-5.722] 0.011 2.339 [1.212-4.516] 
APACHE = Acute Physiology and Chronic Health Evaluation; SOFA = Sequential organ failure assessment; 
RRT = renal replacement therapy; COPD = chronic obstructive pulmonary disease; HIV = human 
immunodeficiency virus; BMI = body mass index; IA = Invasive aspergillosis. 
Discussion 
In this cohort of 563 patients with an Aspergillus-positive culture, 53% was diagnosed with 
putative or proven IA. Compared to Aspergillus-colonized patients, IA patients had more 
cancer, organ transplantation, sepsis/ARDS on admission, needed more supportive therapy, 
and had higher mortality. Patients with proven IA had more frequently medical admissions 
and higher SOFA scores than patients with putative IA, but outcomes were similar. Older 
age, bone marrow transplantation, higher SOFA scores and mechanical ventilation or RRT 
were independently associated with a poor outcome. 
The true epidemiology of IA remains uncertain and depends on case-mix, environmental 
factors, and diagnostic strategy. In our cohort, clinical and radiological manifestations were 
non-specific and possibly masked by the underlying acute process. Although Barberan et al. 
showed that radiological worsening or cavitation on chest X-ray/CT-scan was associated with 
IA [30], in another series up to 60% of cases of IA were exclusively diagnosed by autopsy 
because of lack of reliable clinical and radiological tests [7]. Moreover, in an ICU cohort, 
only 12 on 67 ICU patients with proven IA had a halo-sign or cavitation on chest CT-scan 
[14]. To overcome these limitations, BAL GM has been suggested, which, with a cut-off of 
0.5, had 88% sensitivity and 87% specificity to detect IA, whereas sensitivity of serum GM 
was only 42% [5]. In our study, we found a higher proportion of proven and putative IA cases 
with positive GM levels (both 84%) when compared to only 18% in colonized patients. 
However, with GM in ICU patients being limited to suspected cases [6,30], use of a clinical 
algorithm to discriminate colonization from IA [23] remains a valid option for identifying 
patients for a more extensive work-up. 
Few studies report on the epidemiology of IA in ICUs. In a large US cohort, ICU patients 
with aspergillosis had several comorbid diseases, high mortality, prolonged hospitalization, 
and increased costs [18]. Specifically, over 70% of patients needed ventilation and received 
high-dose corticosteroids; over 35% had acute renal failure, COPD or septic shock. In a 
multicenter Italian study, aspergillosis represented 35 of 384 invasive mycoses in ICU 
patients [31]. Previous corticosteroid administration for autoimmune disease or COPD was 
the major host factor associated with IA. IA occurred more frequently in medical patients and 
mortality attributed to aspergillosis was higher compared to candidiasis (63% vs. 46%, p = 
0.01). These studies, however, only considered possible and proven IA. Petri et al. isolated 
Aspergillus in only 4% of 435 non-neutropenic ICU patients while none had IA [32]. 
Contrastingly, in the present study, Aspergillus isolation appeared to represent IA in over 
50% of patients. Immunosuppression and sepsis/ARDS on ICU admission were more 
frequent in proven/putative IA than in colonization. A particular feature of this study was the 
finding that an alternative diagnostic algorithm in patients with Aspergillus-positive 
respiratory tract cultures encompassed a larger segment of the burden of IA than the stricter 
EORTC/MSG criteria [9]. Hence, identification of risk factors for IA may help determine 
which ICU patients would benefit from specific screening when an Aspergillus-positive 
culture is found. Another new finding is that we could describe the epidemiology of non-
pulmonary Aspergillus cultures in ICU patients, which were predominantly associated with 
proven IA as affected organs were frequently considered sterile body sites such as the brain 
[33]. 
Pulmonary IA has been documented in 15% of bone marrow transplant patients [34]. 
Prolonged neutropenia or solid organ transplantation also have been identified as high-risk 
factors [34-37]. These conditions are rare in ICU patients. In one study, only 14% of ICU 
patients with IA were neutropenic [7]. Risk factors for IA in ICU patients include COPD, 
liver cirrhosis and severe sepsis [38,39]. In COPD patients, the incidence of Aspergillus 
isolates from lower respiratory tract samples has increased progressively [40]. In a study of 
118 COPD patients, nearly 60% was colonized and 48 patients had IA [41]; IA patients were 
more likely to have advanced respiratory disease, as suggested by the Global initiative for 
Obstructive Lung Disease (GOLD) classification. IA patients had higher severity scores and 
had worse prognoses than Aspergillus-colonized patients. The emergence of IA in patients 
with COPD is mainly attributed to prolonged administration of corticosteroids [42]. 
Corticosteroids also represent a risk for IA in ICU patients receiving immunosuppression 
following solid organ transplant or autoimmune disease [14]. Corticosteroids predispose to 
opportunistic infections through quantitative and qualitative functional impairment of 
macrophages and neutrophil function [42]. Liver cirrhosis also unfavorably alters humoral 
and cellular immune response or complement activity, thereby increasing the risk for 
infections [43]. Finally, sepsis-associated immune-regulatory disturbances, such as 
macrophage deactivation and altered cellular immune response, can induce a state of 
immunoparalysis hampering adequate host response to fungal disease [44]. Recently, IA was 
also associated with H1N1 infection, suggesting that viral infections may play a causal role 
[45]. Unfortunately, we did not collect data on H1N1 co-infection. Finally, we also found that 
higher SOFA scores and RRT requirement, was associated with IA. 
We reported a 72% 12-week mortality in IA patients. In a study on medical ICU patients, 
mortality was 92% [46]; however, most of these patients experienced hematological disease 
or neutropenia, which may have influenced survival. In our study, a minority of patients had 
cancer and/or immunosuppressive therapies and our findings provide interesting data also on 
general ICU population. Mortality rates have improved in ICU patients developing IA. A 
recent study focusing on hospitalized patients with IA reported a crude mortality rate of 37% 
[47]. In another study, mortality for IA was 50% [6]. However, because IA often develops in 
patients with greater disease severity, it remains difficult to determine whether this fungal 
disease contributes per se to the poor outcome or if it is just a marker of disease severity. 
Khasawneh et al. reported a 15% greater mortality among ICU patients with IA than that 
predicted by APACHE II [6]; these authors also showed similar mortality rates in patients 
with colonization and those with invasive disease. Another study estimated the attributable 
mortality for IA to be 19% [48]. Both studies [6,48] were biased by the lack of a diagnostic 
approach to differentiate colonization from IA; also, the availability of more effective 
antifungal agents in the later study may have explained the differences. In our study, patients 
with putative and proven IA had significantly higher mortality rates than colonized patients; 
however, after adjustment for several confounders, this difference remained significant only 
for proven IA. Older age, bone marrow transplantation, higher SOFA scores, need for 
mechanical ventilation or RRT, predicted poor outcome in IA. These findings highlight the 
need for a more timely diagnostic approach to evaluate the effect of earlier initiation of 
therapy. 
Our study has some limitations. First, we could not analyze a specific multimodal diagnostic 
approach as only a minority of patients had CT-scans and GM measurements. Moreover, we 
did not specifically collect whether GM measurement was performed in blood, BAL or other 
biological fluids sampling. The rare use of GM in the diagnostic algorithm could be related to 
the cost of the analysis and/or to its delayed implementation, as the study initiated before the 
publication of the most important papers dealing with GM assessment in critically ill patients 
[5,22]. Additionally, we only included patients with Aspergillus-positive culture, thereby 
excluding patients with suspected disease based on radiological imaging or biomarkers. 
Second, we did not assess reasons for death and cannot exclude that some patients died 
because of concomitant conditions. Third, we did not collect any data on the incidence of 
positive Aspergillus cultures on the total number of ICU admission to the participating 
centers over the study period; thus, we could not evaluate the burden of this disease among 
critically ill patients. Importantly, IA remains a rare disease and it was reported in 1-2% of 
ICU patients in a large international database [10]. Fourth, we did not record laboratory data 
in detail, which may have been useful to better characterize the cohort. We also did not 
collect data on daily corticosteroid dose and could not fully explore the impact of dose or 
duration on mortality. Importantly, we did not collect the amount of antibacterial drugs that 
patients received before IA diagnosis and whether this may have influenced on the 
development of the disease. Fifth, routine autopsy would have increased the number of cases 
of IA diagnosis; autopsy studies have shown that IA is the most frequently missed infectious 
diagnosis in patients requiring ICU admission [15,49,50]. Sixth, we did not consider 
environmental sources of IA, such as construction works contaminating hospital air [51,52]. 
Seventh, a part of these data has already been included a previous publication; however, we 
focused on epidemiology findings while the previous study aimed to validate the diagnostic 
accuracy of a clinical algorithm. Finally, we did not report data on the differences among the 
drugs used to treat Aspergillus spp. in this cohort, although the drug of choice in non-
neutropenic patients needs to be further studied [53]. 
Conclusions 
Compared to Aspergillus-colonized patients, those with IA more frequently had sepsis or 
respiratory failure on admission, had more underlying conditions including 
immunocompromized status. IA patients had higher disease severity and needed more organ 
support. IA in the ICU is associated with an unacceptably high mortality rate. 
Key messages 
• In this multicentric cohort of ICU patients, half of patients with a positive Aspergillus 
culture had either putative or proven IA 
• Patients with IA were more frequently immunosuppressed than those with colonization; 
however, sepsis and higher severity of illness were also more frequent 
• Mortality in patients with IA was significantly higher than in those with Aspergillus 
colonization, even after adjustment for several risk factors. 
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Appendix 2 
The clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients 
[23]. 
Proven invasive pulmonary aspergillosis 
Microscopic analysis on sterile material: histopathologic, cytopathologic, or direct 
microscopic examination of a specimen obtained by needle aspiration or sterile biopsy in 
which hyphae are seen accompanied by evidence of associated tissue damage. Culture on 
sterile material: recovery of Aspergillus by culture of a specimen obtained by lung biopsy 
Putative invasive pulmonary aspergillosis (all four criteria must be met) 
1. Aspergillus-positive lower respiratory tract specimen culture (= entry criterion) 
2. Compatible signs and symptoms (one of the following) 
– Fever refractory to at least 3 d of appropriate antibiotic therapy 
– Recrudescent fever after a period of defervescence of at least 48 h while still on 
antibiotics and without other apparent cause 
– Pleuritic chest pain 
– Pleuritic rub 
– Dyspnea 
– Hemoptysis 
– Worsening respiratory insufficiency in spite of appropriate antibiotic therapy and 
ventilatory support 
 
3. Abnormal medical imaging by portable chest X-ray or CT scan of the lungs 
4. Either 4a or 4b 
4a Host risk factors (one of the following conditions) 
  Neutropenia (absolute neutrophil count <500/mm
3
) preceding or at the time of ICU 
admission 
  Underlying hematological or oncological malignancy treated with cytotoxic agents 
  Glucocorticoid treatment (prednisone equivalent > 20 mg/d) 
  Congenital or acquired immunodeficiency 
 
4b Semi-quantitative Aspergillus-positive culture of BAL fluid (+ or ++), without bacterial 
growth together with a positive 
  cytological smear showing branching hyphae 
 
 
Aspergillus respiratory tract colonization 
When >1 criterion necessary for a diagnosis of putative IPA is not met, the case is classified 
as Aspergillus colonization. 
BAL = broncho-alveolar lavage; CT = computed tomography; ICU = intensive care unit. 
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